Phase II study of the combination Bendamustine and sc Alemtuzumab for patients with refractory or relapsed B-cell chronic lynphocytic leukaemia.

Trial Profile

Phase II study of the combination Bendamustine and sc Alemtuzumab for patients with refractory or relapsed B-cell chronic lynphocytic leukaemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2013

At a glance

  • Drugs Alemtuzumab (Primary) ; Bendamustine (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Acronyms BEN-CAM
  • Most Recent Events

    • 30 Nov 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 29 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top